News

Eli Lilly’s $1.3 Billion Bid Sends Verve Therapeutics Stock Soaring. What to Know.
Lilly confirmed it would buy a Boston-based clinical-stage company developing genetic medicines for cardiovascular disease.
Eli Lilly: The Buy Case Gets Stronger (Rating Upgrade)
Eli Lilly's stock price has over-corrected following a downgrade in its outlook following the adjustment for acquisition ...
Eli Lilly strikes deal to buy Crispr gene-editing biotech Verve
Eli Lilly has struck a deal to buy Crispr gene-editing start-up Verve Therapeutics for up to $1.3bn, the latest acquisition ...
Eli Lilly’s Dividend May Be Small, But its Growth Tells a Bigger Story
Eli Lilly and Company (NYSE:LLY) may offer a modest dividend yield, but its track record of consistent payouts remains strong ...
Eli Lilly to acquire gene-editing biotech company Verve Therapeutics for $1.3 billion. Here's why
US Big Pharma firm Eli Lilly & Co. agreed to buy gene-editing biotech company Verve Therapeutics Inc. for $1.3 billion as the ...
Lilly spends $1B on Boston biotech developing gene-editing cholesterol drug
Eli Lilly and Co. is shelling out $1 billion to buy a Boston biotech known for genetic medicines for cardiovascular disease.
Eli Lilly, Juvena Therapeutics Partner to Develop Muscle-Boosting Drugs Using AI Platform
Eli Lilly and Company (NYSE:LLY) is one of the best stocks to buy for beginners now. On June 11, Eli Lilly announced a ...
Lilly to offer highest doses of weight-loss drug Zepbound on website
Eli Lilly will ship the two highest doses of its popular weight-loss drug Zepbound to cash-paying customers on its website ...
The Zacks Analyst Blog Highlights Eli Lilly, Home Depot, SAP and Natural Resource Partners
Eli Lilly, Home Depot, SAP and NRP highlight key themes in pharma, retail, cloud growth???and energy sector challenges.